Other Intangible Assets, Net

6 Months Ended

Jun. 30, 2012

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Other Intangible Assets Disclosure

6.       Other intangible assets, net

		June 30,	December 31,
		2012	2011
		$’M	$’M
		________________	________________
Amortized intangible assets
	Intellectual property rights acquired for currently marketed products	2,548.1	2,500.7
	Acquired product technology	710.0	710.0
	Other intangible assets	45.1	23.2
		________________	________________
		3,303.2	3,233.9
Unamortized intangible assets
	Intellectual property rights acquired for IPR&D	277.9	119.8
		________________	________________
		3,581.1	3,353.7
Less: Accumulated amortization		(955.5)	(860.7)
		________________	________________
		2,625.6	2,493.0
		________________	________________

As at June 30, 2012 the net book value of intangible assets allocated to the SP segment was $ 1,444.7 million (December 31, 2011: $1,348.3 million),to the HGT segment was $484.5 million (December 31, 2011: $453.2 million) and to the RM segment was $696.4 million (December 31, 2011: $691.5 million).

The change in the net book value of other intangible assets for the six monthsto June 30, 2012 and 2011is shown in the table below:

	Other intangible assets
	2012	2011
	$’M	$’M
	________________	________________
As at January 1,	2,493.0	1,978.9
Acquisitions	272.5	711.5
Amortization charged	(97.3)	(73.6)
Impairment charges	(27.0)	-
Foreign currency translation	(15.6)	62.6
	________________	________________
As at June 30,	2,625.6	2,679.4
	________________	________________

Management estimates that the annual amortization charge in respect of intangible assets held at June 30, 2012 will be approximately $202.6million for each of the five years to June 30, 2017.Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of acquired IPR&D projects, foreign exchange movements and the technological advancement and regulatory approval of competitor products.